Released Nov 4, 2026, before the open
10-Q filed Nov 4, 2026, 35 days after period end · 0001082554-26-000035
Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $832.50M | $799.50M | $748.90M | $609.40M |
| Net Income | $258.60M | $338.70M | $309.10M |
United Therapeutics Corp · CIK 1082554 · Engraved from SEC EDGAR
| $267.60M |
| EPS Diluted | $5.71 | $7.16 | $6.39 | $5.38 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
United Therapeutics reported total revenues of $832.5 million for the third quarter of 2026, up from $799.5 million a year earlier.¶1
Net income was $258.6 million for the quarter, compared with $338.7 million a year earlier, as research and development expense rose to $279.2 million.¶2¶3
Total Tyvaso revenues rose five percent to $503.8 million, driven by Tyvaso DPI growth that was partially offset by lower Nebulized Tyvaso revenues.¶4
Income tax expense was $114.2 million, giving an effective tax rate of 31 percent, compared with 23 percent a year earlier.¶5
In October 2026, the Board of Directors approved a new share repurchase program authorizing up to $2.0 billion through October 21, 2027.¶6